Page 125 - 《中国药房》2022年12期

参考文献 [15] ALLEGRA S，DI PAOLO A，CUSATO J，et al. A common
[ 1 ] 陈胜兰，祝春亚，周华，等.利奈唑胺治疗耐甲氧西林金黄 MDR1 gene polymorphism is associated with changes in
色葡萄球菌血流感染的效果及安全性[J].中华医学杂 linezolid clearance[J]. Ther Drug Monit，2018，40（5）：
志，2017，97（14）：1084-1088. 602-609.
[ 2 ] 王月芳，钟伟，陈东琳.利奈唑胺、替考拉宁及万古霉素治 [16] MINICHMAYR I K，SCHAEFTLEIN A，KUTI J L，et al.
疗院内 MRSA 肺炎的临床观察[J].中国药房，2016，27 Clinical determinants of target non-attainment of linezolid
（26）：3708-3710. in plasma and interstitial space fluid：a pooled population
[ 3 ] FUJII M，KARUMAI T，YAMAMOTO R，et al. Pharma- pharmacokinetic analysis with focus on critically ill patients
cokinetic and pharmacodynamic considerations in antimi- [J]. Clin Pharmacokinet，2017，56（6）：617-633.
crobial therapy for sepsis[J]. Expert Opin Drug Metab [17] DOU L J，MENG D D，DONG Y L，et al. Dosage regimen
Toxicol，2020，16（5）：415-430. and toxicity risk assessment of linezolid in sepsis patients
[ 4 ] GILBERT D N，CHAMBERS H F，ELIOPOULOS G M， [J]. Int J Infect Dis，2020，96：105-111.
等.热病：桑福德抗微生物治疗指南：新译第48版[M].范 [18] TAUBERT M，ZOLLER M，MAIER B，et al. Predictors
洪伟，主译.北京：中国协和医科大学出版社，2019：96. of inadequate linezolid concentrations after standard do-
[ 5 ] SAZDANOVIC P，JANKOVIC S M，KOSTIC M，et al. sing in critically ill patients[J]. Antimicrob Agents Che-
Pharmacokinetics of linezolid in critically ill patients[J]. mother，2016，60（9）：5254-5261.
Expert Opin Drug Metab Toxicol，2016，12（6）：595-600. [19] TAUBERT M，ZANDER J，FRECHEN S，et al. Optimiza-
[ 6 ] ABDUL-AZIZ M H，ALFFENAAR J W C，BASSETTI M， tion of linezolid therapy in the critically ill：the effect of
et al. Antimicrobial therapeutic drug monitoring in criti- adjusted infusion regimens[J]. J Antimicrob Chemother，
cally ill adult patients：a position paper[J]. Intensive Care 2017，72（8）：2304-2310.
Med，2020，46（6）：1127-1153. [20] PEA F，COJUTTI P G，BARALDO M. A 10-year ex-
[ 7 ] HEFFERNAN A J，MOHD SAZLLY LIM S，LIPMAN J， perience of therapeutic drug monitoring（TDM）of linezolid
et al. A personalised approach to antibiotic pharmacokine- in a hospital-wide population of patients receiving conven-
tics and pharmacodynamics in critically ill patients[J]. tional dosing：is there enough evidence for suggesting
Anaesth Crit Care Pain Med，2021，40（6）：100970. TDM in the majority of patients? [J]. Basic Clin Pharma-
[ 8 ] 张雷，白楠，刘又宁，等.利奈唑胺在中国人的群体药代动 col Toxicol，2017，121（4）：303-308.
力学特点[J].中华结核和呼吸杂志，2016，39（12）：924- [21] COJUTTI P G，BARBARINO C，DE MONTE A，et al.
928. Higher than standard meropenem and linezolid dosages
[ 9 ] TSUJI Y，HOLFORD N H G，KASAI H，et al. Population needed for appropriate treatment of an intracerebral he-
pharmacokinetics and pharmacodynamics of linezolid- morrhage patient with augmented renal clearance[J]. Eur J
induced thrombocytopenia in hospitalized patients[J]. Br J Clin Pharmacol，2018，74（8）：1091-1092.
Clin Pharmacol，2017，83（8）：1758-1772. [22] BARRASA H，SORALUCE A，USÓN E，et al. Impact of
[10] CATTANEO D，GERVASONI C，COZZI V，et al. Thera- augmented renal clearance on the pharmacokinetics of
peutic drug management of linezolid：a missed opportu- linezolid：advantages of continuous infusion from a phar-
nity for clinicians[J]. Int J Antimicrob Agents，2016，48 macokinetic/pharmacodynamic perspective[J]. Int J Infect
（6）：728-731. Dis，2020，93：329-338.
[11] MORATA L，DE LA CALLE C，GÓMEZ-CERQUERA J [23] WANG X P，WANG Y F，YAO F，et al. Pharmacokinetics
M，et al. Risk factors associated with high linezolid trough of linezolid dose adjustment for creatinine clearance in
plasma concentrations[J]. Expert Opin Pharmacother， critically ill patients：a multicenter，prospective，open-
2016，17（9）：1183-1187. label，observational study[J]. Drug Des Devel Ther，2021，
[12] EHMANN L，SIMON P，BUSSE D，et al. Risk of target 15：2129-2141.
non-attainment in obese compared to non-obese patients [24] FURUKAWA M，KINOSHITA K，YAMAGUCHI J，et al.
in calculated linezolid therapy[J]. Clin Microbiol Infect， sepsis patients with complication of hypoglycemia and
2020，26（9）：1222-1228. hypoalbuminemia are an early and easy identification of
[13] CORCIONE S，PAGANI N，BAIETTO L，et al. Pharmaco- high mortality risk[J]. Intern Emerg Med，2019，14（4）：
kinetics of high dosage of linezolid in two morbidly obese 539-548.
patients[J]. J Antimicrob Chemother，2015，70（8）：2417- [25] DAI Y，JIANG S Y，CHEN X O，et al. Analysis of the risk
2418. factors of linezolid-related haematological toxicity in
[14] CHELI S，FUSI M，DE SILVESTRI A，et al. In linezolid Chinese patients[J]. J Clin Pharm Ther，2021，46（3）：807-
underexposure，pharmacogenetics matters：the role of 813.
CYP3A5[J]. Biomed Pharmacother，2021，139：111631. [26] 孟丹丹，陈利红，董亚琳，等.肝损伤患者利奈唑胺的治疗

中国药房 2022年第33卷第12期 China Pharmacy 2022 Vol. 33 No. 12 ·1523 ·